1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer
  4. >>Immuno-oncology

AbbVie Bails On Harpoon’s Multiple Myeloma Drug Amid Highly Competitive Environment

 
• By Alaric DeArment

Harpoon said it plans to complete the Phase I study of its anti-BCMA immuno-oncology agent HPN217 and use the data to support the next phase of development for the drug.

AbbVie decided not to exercise its option for Harpoon's multiple myeloma drug candidate • Source: Shutterstock

Harpoon Therapeutics’s BCMA-directed T-cell engager candidate for multiple myeloma faces a murky path ahead following a decision by partner AbbVie Inc. not to move forward with the asset, amid a market for anti-BCMA drugs that has become increasingly crowded.

The South San Francisco, CA-based biotech company said 13 September that AbbVie had decided not to exercise its exclusive license...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immuno-oncology

More from Anticancer

Nuvation Set For First Launch With Ibtrozi In Lung Cancer

 
• By Jessica Merrill

The US FDA approved taletrectinib for the treatment of ROS1+ NSCLC, where Nuvation hopes it will lead the category with a best-in-class position.

ASCO: Kite’s Glioblastoma CAR-T Highlights Solid Tumor Progress

 
• By Alaric DeArment

The company presented Phase I data for CART-EGFR-IL13Rα2, showing patient responses in the notoriously hard-to-treat and deadly brain cancer.

Will Pfizer Walk Away From Arvinas After PROTAC Disappointment?

 
• By Andrew McConaghie

Arvinas and Pfizer have just filed the potential first-in-class protein degrader vepdegestrant, but its diminished commercial prospects after mixed Phase III data mean Pfizer could exit.